Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: ‘Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero’ by Satis<i>et al</i>

Mofors, Johannes; Sonesson, Sven‐Erik; Wahren‐Herlenius, Marie

doi:10.1136/annrheumdis-2019-215677

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are no standard guidelines for the management of CHB, treatment mainly consists in fluorinated steroids (dexamethasone or betamethasone) [11]. While treating early signs of 2 nd degree CHB with fluorinated steroids together with intravenous immunoglobulins (IVIG) seems to induce regression of an incomplete CHB [12], there is no evidence that the use of antenatal fluorinated corticosteroids alone can improve fetal/neonatal CHB morbidity or mortality [13,14].…”

Section: Introductionmentioning

confidence: 99%

Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study

et al. 2022

View full text Add to dashboard Cite

Objective The short and long-term outcomes of children with anti-Ro/La-related congenital heart block treated with a combined maternal-neonatal therapy protocol were compared with those of controls treated with other therapies.Study design Sixteen mothers were treated during pregnancy with a therapy consisting of daily oral fluorinated steroids, weekly plasma exchange and fortnightly intravenous immunoglobulins and their neonates with intravenous immunoglobulins (study group); 19 mothers were treated with fluorinated steroids alone or associated to intravenous immunoglobulins or plasma exchange (control group).Result The combined-therapy children showed a significantly lower progression rate from 2 nd to 3 rd degree block at birth, a significant increase in heart rate at birth and a significantly lower number of pacemaker implants during post-natal follow-up with respect to those treated with the other therapies. ConclusionThe combined therapy produced better short and long term outcomes with respect to the other therapies studied.

show abstract

Section: Introductionmentioning

confidence: 99%